Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI

Colorectal Cancer Clinical Trial

Official title:

Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI Regimen (Folinic Acid, 5-fluorouracil, Oxaliplatin and Irinotecan)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03504618
• Other study ID #: HMU16223
• Status: Completed
• First received: April 4, 2018
• Last updated: April 12, 2018
• Start date: January 1, 2017
• Est. completion date: February 1, 2018

Study information

• Verified date: April 2018
• Source: Hanoi Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Colon cancer with metastase in the diagnose time account for one significant rate and has a increasing trend. The treatment result of this patient group rests modest. The biological therapeutic treatment is still expensive for major part of Vietnamese patients. So that, research on a new affordable and efficacious chemotherapy combination for these patients is extremely necessary in our country The purpose of the study is to comment somes clinico-pathology features of metastatic colon cancer patients whose disease was not radically resectable.

The second aim is to Evaluate the treatment result and toxicity of FOLFOXIRI in these patients

Description:

In the world, colorectal cancer is the third most common cancer in male and the second most common cancer in female. In VietNam, the disease is the fourth cancer in male, the sixth cancer in female and increasing recently. About 20-40% of the colon cancer patients had distant metastasis at the time of diagnose, those treatment outcome remains poor (5years survival is about 11%). The targetted therapy medications are still not affordable for majority of Vietnamese patients. So that, 3 cytotoxic drugs (5-Fluoro-Uracil, Oxaliplatin and Irinotecan) remain back-bone in the treatment of metastatic colon cancer.

According to one meta-analysis, the overall survival rate significantly correlated to the use of all 3 these drugs in the treatment time. If patients were give two drugs as the doublet in a line (FOLFOX/XELOX, FOLFIRI/XELIRI), not 100% of patients are treated with all 3 these drugs because some abandonned the following treatment lines. So, the trials that give all 3 drugs in a line (first-line) as triplet (FOLFOXIRI) were carried out and had primirily good outcome. In 2010, FOLFOXIRI were recommended in NCCN guideline.

In VietNam, FOLFOXIRI has been applied to treat patient since 2013. However, since then there was no clinical trial to evaluate the efficacy and the toxicity of this combination. Therefore, we carried out the work "Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI"

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: February 1, 2018
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 39 colon cancer patients with metastase at the diagnotic time, impossiblity of radical resection, adenocarcinoma, treated by at least 3 cylces of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department, Ha Noi medical university hospital, from September 2013 to April 2017

Related Conditions & MeSH terms

• Colonic Neoplasms
• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• FOLFOXIRI
Treatment of FOLFOXIRI regimen at first line with dosage: Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day

Locations

Country	Name	City	State
Vietnam	Hanoi Medical University	Hanoi

Sponsors (1)

Lead Sponsor	Collaborator
Hanoi Medical University

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patients' characteristic	Clinico-pathology features of metastatic colon cancer patients whose disease was not radically resectable	4 years
Primary	Response rate after 3 cycles	Responses are evaluated according to WHO criteria. The determination of responses and progression was initially based on investigator-reported measurements; computed tomography scans of all responding patients and of patients with stable disease were subsequently subjected to external review by an independent panel.	At the end of Cycle 3 (each cycle is 4 weeks)
Primary	Response rate after 6 cycles	Responses are evaluated according to WHO criteria. The determination of responses and progression was initially based on investigator-reported measurements; computed tomography scans of all responding patients and of patients with stable disease were subsequently subjected to external review by an independent panel.	At the end of Cycle 6 (each cycle is 4 weeks)
Primary	Correlation between response rate and percentage of chemotherapy dosage	Prognostic factor of response rate	4 years
Primary	Correlation between response rate and histopathology	Prognostic factor of response rate	4 year
Primary	Correlation between response rate and metastatic site	The average size of the hepatic metastatic lesion in the study	4 years
Primary	Prognostic factor for response rate after 3 cycles	Evaluation of predictor of response rate	At the end of cycle 3 (each cycle is 4 weeks)
Primary	Prognostic factor for response rate after 6 cycles	Evaluation of predictor of response rate	At the end of cycle 6 (each cycle is 4 weeks)
Primary	Mean of the progression free survival	The median progression free survival of the study population	4 years
Primary	Prognostic factor of progression free survival	Evaluation of predictor of progression free survival	4 years
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	During the full length of first-line treatment, number of enrolled patients reporting adverse events is recorded. Adverse events are evaluated according to National Cancer Institute Common Toxicity Criteria latest version.	4 years
Secondary	Overall survival after 12 months	The percentage of survival patients 12 month after finishing treatment with FOLFOXIRI regimen	12 months after the last patient finish chemotherapy
Secondary	Overall survival after 24 months	The percentage of survival patients 24 month after finishing treatment with FOLFOXIRI regimen	24 months after the last patient finish chemotherapy